drugset / Trial / NCT00020475

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475

Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy and interleukin-2 in treating patients who have metastatic melanoma of the eye.

Timeline

Start
2001-02
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MART-1 antigen Vaccine Subcutaneous
Subject aldesleukin Protein / enzyme biologic Intravenous
Subject gp100 antigen Peptide Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified